A. Patick

发表

Conservation of Amino Acids in Human Rhinovirus 3C Protease Correlates with Broad-Spectrum Antiviral Activity of Rupintrivir, a Novel Human Rhinovirus 3C Protease Inhibitor

D. Matthews, F. Maldonado, S. Binford, 2005, Antimicrobial Agents and Chemotherapy.

Protease Inhibitor Rupintrivir , a Novel Human Rhinovirus 3 C Broad-Spectrum Antiviral Activity of Rhinovirus 3 C Protease Correlates with Conservation of Amino Acids in Human

D. Matthews, F. Maldonado, S. Binford, 1982 .

The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan

S. Hammer, S. Yerly, A. Zolopa, 2000, Antiviral therapy.

Treatment of HCV infection by targeting microRNA.

S. Kauppinen, S. Zeuzem, H. Janssen, 2013, The New England journal of medicine.

In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122

L. van Doorn, T. Parsley, A. Patick, 2014, Antimicrobial Agents and Chemotherapy.

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

J. Nieman, S. Butler, G. Ciaramella, 2010, PLoS pathogens.

Rapid multiserotype detection of human rhinoviruses on optically coated silicon surfaces

B. Polisky, S. Worland, L. Zalman, 2001, Journal of Clinical Virology.

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

D. Ho, M. Markowitz, H. Mo, 1996, Antimicrobial agents and chemotherapy.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.

Bo Liu, Rose Ann Ferre, Tove Tuntland, 2002, Journal of medicinal chemistry.

Role of T cell receptor V beta genes in Theiler's virus-induced demyelination of mice.

L. Pease, M. Rodriguez, A. Patick, 1992, Journal of immunology.

Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

C. Lewis, S. Shi, S. Binford, 2009, Antimicrobial Agents and Chemotherapy.

Development of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors

S. Shi, R. Duggal, A. Patick, 2008, Antimicrobial Agents and Chemotherapy.

In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

M. Hickey, H. Parge, C. Lewis, 2007, Antimicrobial Agents and Chemotherapy.

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.

N. Chirgadze, D. Clawson, K. Appelt, 1997, Journal of medicinal chemistry.

Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluation.

D. Matthews, T. Hendrickson, R. Ferre, 2000, Journal of medicinal chemistry.

Inhibition of Theiler's virus-induced demyelination in vivo by tumor necrosis factor alpha.

Moses Rodriguez, C. Payá, M. Rodriguez, 1990, International immunology.

Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers

M. Gersten, F. Hayden, R. Turner, 2003, Antimicrobial Agents and Chemotherapy.

Role of natural killer cells as immune effectors in encephalitis and demyelination induced by Theiler's virus.

Moses Rodriguez, C. Payá, M. Rodriguez, 1989, Journal of immunology.

Coexpression of class I major histocompatibility antigen and viral RNA in central nervous system of mice infected with Theiler's virus: a model for multiple sclerosis.

M. Rodriguez, A. Patick, M. Lindsley, 1992, Mayo Clinic proceedings.

Molecular Characterization of a Nondemyelinating Variant of Daniel’s Strain of Theiler’s Virus Isolated from a Persistently Infected Glioma Cell Line

Moses Rodriguez, L. Pease, R. Roos, 1998, Journal of Virology.

Inhibition of Human Rhinovirus-Induced Cytokine Production by AG7088, a Human Rhinovirus 3C Protease Inhibitor

P. Dragovich, S. Worland, M. A. Brothers, 2000, Antimicrobial Agents and Chemotherapy.

An optical thin film assay incorporating rhinovirus protease inhibitors as detector reagents.

B. Polisky, P. Dragovich, S. Worland, 2004, Antiviral research.

Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides.

P. Dragovich, S. Worland, J. Meador, 1999, Bioorganic & medicinal chemistry.

Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.

D. Matthews, T. Hendrickson, S. Webber, 1998, Journal of medicinal chemistry.

Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities

A. Patick, S. Webber, E. Wu, 2001, Antimicrobial Agents and Chemotherapy.

Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.

D. Matthews, T. Hendrickson, S. Webber, 1996, Journal of medicinal chemistry.

Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy.

Hui Li, R. E. Anderson, R. Colonno, 1994, The Journal of infectious diseases.

Major histocompatibility complex-conferred resistance to Theiler's virus-induced demyelinating disease is inherited as a dominant trait in B10 congenic mice

L. Pease, M. Rodriguez, A. Patick, 1990, Journal of virology.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.

D. Matthews, P. Rejto, P. W. Rose, 2003, Journal of medicinal chemistry.

In Vitro Antiviral Activity of AG7088, a Potent Inhibitor of Human Rhinovirus 3C Protease

D. Matthews, M. Diem, P. Dragovich, 1999, Antimicrobial Agents and Chemotherapy.

Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

D. Matthews, T. Hendrickson, S. Webber, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids.

D. Matthews, S. Webber, P. Dragovich, 1999, Bioorganic & medicinal chemistry letters.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.

D. Matthews, P. Rejto, T. Hendrickson, 1999, Journal of medicinal chemistry.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.

D. Matthews, P. Dragovich, R. Ferre, 1999, Journal of medicinal chemistry.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.

D. Matthews, R. Babine, S. Webber, 1998, Journal of medicinal chemistry.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.

D. Matthews, R. Babine, S. Webber, 1998, Journal of medicinal chemistry.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.

Rose Ann Ferre, D. Matthews, P. Dragovich, 2002, Bioorganic & medicinal chemistry letters.

Design , Synthesis , and Evaluation of Nonpeptidic Inhibitors of Human Rhinovirus 3 C Protease

D. Matthews, T. Hendrickson, S. Webber, 2022 .

Protease Inhibitors as Antiviral Agents

A. Patick, K. E. Potts, A. K. Patick, 1998, Clinical Microbiology Reviews.

High-Throughput Human Immunodeficiency Virus Type 1 (HIV-1) Full Replication Assay That Includes HIV-1 Vif as an Antiviral Target

W. Blair, A. Patick, Joan Q. Cao, 2005, Antimicrobial Agents and Chemotherapy.

A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors.

W. Blair, A. Patick, Joan Q. Cao, 2005, Antiviral research.

Biochemical and biophysical characteristics of Rio Bravo virus (Flaviviridae).

A. Patick, L. Petti, A. J. Hall, 1988, The Journal of general virology.

Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors.

D. Matthews, S. Webber, P. Dragovich, 2000, Bioorganic & medicinal chemistry letters.

Synthesis and antiviral activity of methyl derivatives of 9-[2-(phosphonomethoxy)ethyl]guanine.

J. C. Martin, A. Patick, J. Bronson, 1992, Journal of medicinal chemistry.

Substituted naphthalenones as a new structural class of HIV-1 reverse transcriptase inhibitors.

R. Colonno, A. Patick, A. Meyers, 1993, Antiviral research.

Synthesis and Antiviral Activity of Methyl Derivatives of 9-(2-( Phosphonomethoxy)ethyl)guanine.

A. Patick, J. Bronson, R. Datema, 1992 .

Potential use of antiviral agents in polio eradication.

E. De Clercq, J. Neyts, B. Rombaut, 2008, Emerging infectious diseases.

In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.

S. Binford, A. Patick, T. Fujiwara, 2006, Antiviral research.

Synthesis and antiviral activity of 2'-substituted 9-[2-(phosphonomethoxy)ethyl]guanine analogues.

J. C. Martin, A. Patick, J. Bronson, 1993, Journal of medicinal chemistry.

Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro

D. Smee, P. Blair, M. D. de Jong, 2010, PloS one.

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection.

D. Ho, A. Hurley, M. Markowitz, 1998, The Journal of infectious diseases.

Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir

D. R. Kuritzkes, Y. Cao, D. Kuritzkes, 1998, Antimicrobial Agents and Chemotherapy.

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

A. Pavlícek, N. Kootstra, M. van der Valk, 2017, The Lancet.

Persistent infection of a glioma cell line generates a Theiler's virus variant which fails to induce demyelinating disease in SJL/J mice.

M. Rodriguez, J. Leibowitz, A. Patick, 1990, The Journal of general virology.

Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.

A. Patick, K. Maegley, R. Love, 2007, Antiviral research.

Discovery of Two Novel Classes of Inhibitors of Hepatitis C Virus (HCV) Replication utilizing a Dicistronic Reporter HCV Replicon High Throughput Assay

F. Maldonado, R. Duggal, P. Weady, 2007 .

Development of a Novel Dicistronic Reporter-Selectable Hepatitis C Virus Replicon Suitable for High-Throughput Inhibitor Screening

R. Duggal, A. Patick, Weidong Hao, 2006, Antimicrobial Agents and Chemotherapy.

Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro

A. Patick, L. A. Bloom, T. Boritzki, 1997, Antimicrobial agents and chemotherapy.

In Vitro Resistance Study of Rupintrivir, a Novel Inhibitor of Human Rhinovirus 3C Protease

D. Matthews, F. Maldonado, S. Binford, 2007, Antimicrobial Agents and Chemotherapy.

In Vitro Antiviral Activity and Single-Dose Pharmacokinetics in Humans of a Novel, Orally Bioavailable Inhibitor of Human Rhinovirus 3C Protease

F. Maldonado, S. Binford, M. A. Brothers, 2005, Antimicrobial Agents and Chemotherapy.

Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor

R. Colonno, A. Patick, R. White, 1996, Antimicrobial agents and chemotherapy.

Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.

P. Tebas, W. Powderly, A. Patick, 1999, AIDS.

Characterization of herpesvirus sylvilagus glycoproteins released into the culture medium of infected cells: antisera to gp13 and gp32 neutralize viral infectivity in vitro and identify antigens on plasma membranes of infected cells

A. Patick, H. Hinze, 1987, Journal of virology.

Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor

J. Barrish, M. Hermsmeier, R. Colonno, 1995, Journal of virology.

Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease

J. Barrish, E. Gordon, A. Patick, 1995, Antimicrobial agents and chemotherapy.

HUMAN IMMUNODEFICIENCY VIRUS PROTEASE Since the identification of HIV as the causative agent of AIDS

A. Patick, K. E. Potts, 1998 .

Identification of Biased Amino Acid Substitution Patterns in Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Protease Inhibitors

Volker Brendel, Robert W. Shafer, R. Shafer, 1999, Journal of Virology.

IN VITRO ANTIVIRAL ACTIVITY OF HUMAN RHINOVIRUS 3C PROTEASE INHIBITORS AGAINST THE SARS CORONAVIRUS

D. Matthews, P. Rejto, P. W. Rose, 2004 .

New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation

S. Butler, W. Blair, A. Patick, 2009, Antimicrobial Agents and Chemotherapy.

Identification of herpesvirus sylvilagus-induced polypeptides in productively infected cells

A. Patick, H. C. Hinze, H. Hinze, 1984, Journal of virology.

Herpesvirus Sylvilagus: Lymphoproliferative Agent of Cottontail Rabbits

A. Patick, H. C. Hinze, H. Hinze, 1988 .

Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors.

D. Matthews, B. Srinivasan, S. Webber, 2001, Bioorganic & medicinal chemistry letters.

Identification and Characterization of UK-201844, a Novel Inhibitor That Interferes with Human Immunodeficiency Virus Type 1 gp160 Processing

S. Butler, W. Blair, A. Patick, 2007, Antimicrobial Agents and Chemotherapy.

1202 SEQUENCE ANALYSIS OF HCV VARIANTS FROM A PHASE IIA TRIAL OF MIRAVIRSEN (MIR), AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT NAIVE PATIENTS WITH CHRONIC HCV INFECTION

A. Patick, M. Hodges, K. Zeh, 2012 .

Rhinovirus chemotherapy

A. Patick, Amy K Patick, 2006, Antiviral Research.

Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.

E. Mazabel, A. Patick, J. Isaacson, 2000, The Journal of infectious diseases.

Comparison of human cytomegalovirus (HCMV) protease sequences among laboratory strains and seven clinical isolates.

S. Binford, L. Zalman, A. Patick, 1997, Antiviral research.

Characterization of a Mutant HIV-1 Reverse Transcriptase Resistant to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-imidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150)

R. Colonno, A. Patick, R. Rose, 1994 .

Treatment of HCV infection by targeting microRNA.

S. Kauppinen, S. Zeuzem, H. Janssen, 2013, The New England journal of medicine.